Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contest

1st November 2019 Uncategorised 0

Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Cosentyx failed to outdo AbbVie behemoth Humira in a head-to-head trial in active psoriatic arthritis patients.

More: Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contest
Source: fierce